KarXTA Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Sponsor:

Bristol-Myers Squibb

Code:

NCT06929273

Conditions

Bipolar Disorder Type I With Mania

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

KarXT

Lithium

Valproate

Lamotrigine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-07-24.